Slide 1: Cell Biotech 2024 3Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2024 3Q Earnings Release 2024. 11. 15. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual re
Slide 2: Revenue down 3.1% to KRW 38 billion, operating profit KRW 5.7 billion
CELL BIOTECH Revenue down 3.1% KRW 38 billion, operating profit KRW 5.7 billion Domestic revenue down 19.8%, overseas revenue up 18.2% Duolac brand sales down 18.2% KRW 18.1 billion, OEM/ODM sales up 18.3% to KRW 15.5 billion, Raw material sales up 12.3% to KRW 4.1 billion (unit : KRW 100 mil) 389.5
Slide 3: Q3 revenue down 11% to KRW 12.2 billion, operating profit up 14.9%
CELL BIOTECH Revenue down 11% KRW 12.2 billion, operating profit up 14.9% to KRW 2.1 billion Domestic revenue down 29.8%, overseas revenue up 11.1% Duolac brand sales down 26% KRW 5.5 billion, OEM/ODM sales up 9.1% to KRW 5.5 billion, Raw material sales down 1% KRW 1.11 billion (unit : KRW 100 mil)
Slide 4: 3Q revenue KRW 12.2 billion, yoy -11%
CELL BIOTECH 3q revenue KRW 12.2 billion, yoy -11% Domestic sales decrease 29.8%. Overseas sales increase 11.1% Quarterly revenue Full year revenue (unit: KRW mil) (unit : KRW mil) 53,787 50,526 14,841 13,806 13,660 12,845 13,038 12,418 12,440 12,558 12,160 46,873 22.3Q 22.4Q 23.1Q 23.2Q 23.3Q 23.4Q
Slide 5: Quarterly and full year profit
CELL BIOTECH 3q operating profit KRW 2.1 billion, yoy +14.9% Net interest income +1.0 billion Quarterly profit Full year profit (unit: KRW mil) (unit: KRW mil) OP NP 10,383 5,531 8,281 7,257 3,260 4,040 2,961 6304 2,857 2,707 6,051 2510 2,056 2080 1,696 1,812 2384 960 1,036 1070 3,667 3,189 2195 (2,
Slide 6: 3Q revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH 3q revenue of Duolac brand -26% KRW 5.5 bil., OEM/ODM +9.1% to KRW 5.5 bil., and raw material -1.0% KRW 1.11 bil. 20,000 (unit : KRW mil) 15,000 10,000 5,000 - '21.3Q 21.4Q 22.1Q 22.2Q 22.3Q 22.4Q 23.1Q 23.2Q 23.3Q 23.4Q 24.1Q 24.2Q 24.3Q Duolac-domestic Duolac-overseas OEM/ODM raw mate
Slide 7: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 11 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cell Biotech "Duolac, No. 1 in domestic probiotic exports for 11 clinical phase 1 IND submitted (Mar 5, 2021) consecutive years. 2) Acquisition European patent of P
Slide 8: Income statement and statement of financial position
CELL BIOTECH Income statement (unit : KRW 100 mil., %) Statement of financial position (unit : KRW 100 mil., %) 8